Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13349588 | 0.81 | SLC6A4 (0.38) | SLC6A2SLC6A4OPRM1 | |
| SCHEMBL9733087 | 0.78 | SLC6A4 (0.36) | SLC6A2SLC6A4OPRM1 | |
| SCHEMBL3581871 | 0.77 | SLC6A4 (0.36) | SLC6A2SLC6A4OPRM1 | |
| SCHEMBL9968594 | 0.75 | KMT2A (0.38) | SLC6A2SLC6A4OPRM1 | |
| SCHEMBL29169853 | 0.73 | GAA (0.33) | — | |
| SCHEMBL13652264 | 0.71 | SLC6A2 (0.33) | SLC6A2SLC6A4OPRM1 | |
| SCHEMBL11509005 | 0.71 | SLC6A4 (0.33) | SLC6A2SLC6A4OPRM1 | |
| SCHEMBL13652326 | 0.69 | GAA (0.33) | — | |
| SCHEMBL8402329 | 0.68 | SLC6A2 (0.31) | SLC6A2SLC6A4OPRM1 | |
| SCHEMBL28326540 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8203004-B2 | Tetrahydroindole derivatives for treatment of alzheimer's disease | MERCK, SHARP & DOHME LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-20100016308-A1 | Tetrahydroindole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016308-A1 | Tetrahydroindole Derivatives for Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN2 | SLC6A2 557/4885SLC6A4 603/4885OPRM1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.